Literature DB >> 12201864

Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.

Kunio Okuda1, Yasuni Nakanuma, Masaru Miyazaki.   

Abstract

Part 2 of this review discusses DNA damage in biliary epithelial cells in the development of cholangiocarcinoma, alterations in cell kinetics of biliary epithelial cells, biliary epithelial mitoinhibition, and apoptosis that includes the role of Bcl-2, transforming growth factor-beta, telomerase activities and deregulation of Ras and p53, cancer-associated antigens in cholangiocarcinoma, precancerous lesions, stroma formation and angiogenesis, cancer invasion, cell-cell and cell-matrix interactions, and the mechanism of evasion from immune surveillance. These discussions are followed briefly by treatments such as photodynamic therapy, and surgical approaches comparing resection and liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12201864     DOI: 10.1046/j.1440-1746.2002.02780.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

Review 1.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

2.  Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.

Authors:  Dongdong Lu; Chang Han; Tong Wu
Journal:  Gastroenterology       Date:  2011-02-24       Impact factor: 22.682

3.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

Authors:  Shusaku Ohira; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Yoh Zen; Kumiko Isse; Kazuto Kozaka; Akira Ishikawa; Koji Oda; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

5.  Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness.

Authors:  Ying Xie; Cody J Wehrkamp; Jing Li; Yan Wang; Yazhe Wang; Justin L Mott; David Oupický
Journal:  Mol Pharm       Date:  2016-02-08       Impact factor: 4.939

6.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Authors:  Xiaoling Xu; Shogo Kobayashi; Wenhui Qiao; Cuiling Li; Cuiying Xiao; Svetlana Radaeva; Bangyan Stiles; Rui-Hong Wang; Nobuya Ohara; Tadashi Yoshino; Derek LeRoith; Michael S Torbenson; Gregory J Gores; Hong Wu; Bin Gao; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

7.  Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Shun-Yuan Jiang; Jung-Mao Chou; Fur-Jiang Leu; Yu-Yen Hsu; Yu-Lung Shih; Jyh-Cherng Yu; Meei-Shyuan Lee; Rong-Yaun Shyu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

8.  Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.

Authors:  Keita Itatsu; Motoko Sasaki; Junpei Yamaguchi; Shusaku Ohira; Akira Ishikawa; Hiroko Ikeda; Yasunori Sato; Kenichi Harada; Yoh Zen; Hiroshi Sato; Tetsuo Ohta; Masato Nagino; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

9.  Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.

Authors:  Yijun Xu; Mingchen Zhu; Shuhong Zhang; Hui Liu; Tao Li; Chengyong Qin
Journal:  Pathol Oncol Res       Date:  2009-09-09       Impact factor: 3.201

Review 10.  Mechanisms of biliary carcinogenesis and growth.

Authors:  Candace Wise; Metaneeya Pilanthananond; Benjamin-F Perry; Gianfranco Alpini; Michael McNeal; Shannon-S Glaser
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.